Akcea Therapeutics Inc Quick Ratio (AKCA) starting from the second quarter 2020 to second quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Akcea Therapeutics Inc   (NASDAQ: AKCA)

Akcea Therapeutics Inc 's Quick Ratio

AKCA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2020, Quick Ratio deteriorated to 11.08 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Quick Ratio than Akcea Therapeutics Inc in second quarter 2020. While Quick Ratio total ranking in the second quarter 2020 has deteriorated compared to the prior quarter from 251 to 349.

Explain Quick Ratio?
How much Cash & cash equivalents AKCA´s has?
What are AKCA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AKCA Quick Ratio (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2
Y / Y Current Liabilities Change 1.27 % -31.59 % 22.71 % 33.27 % 21.15 %
Y / Y Cash & cash equivalent Change 31.89 % 30.92 % 83.55 % -21.11 % -22.59 %
Quick Ratio MRQ 11.08 11.6 11.64 7.83 8.51
AKCA's Total Ranking # 349 # 251 # 83 # 325 # 451
Seq. Current Liabilities Change -3.17 % -8.79 % 23.39 % -7.08 % -34.59 %
Seq. Cash & cash equivalent Change -7.46 % -9.14 % 83.49 % -14.52 % -8.14 %



Quick Ratio second quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 168
Overall Market # 349


Quick Ratio Statistics
High Average Low
11.64 9.45 6.06
(Dec 31 2019)   (Mar 31 2019)




Financial Statements
Akcea Therapeutics Inc 's Current Liabilities $ 35 Millions Visit AKCA's Balance sheet
Akcea Therapeutics Inc 's Cash & cash equivalent $ 390 Millions Visit AKCA's Balance sheet
Source of AKCA's Sales Visit AKCA's Sales by Geography


Cumulative Akcea Therapeutics Inc 's Quick Ratio

AKCA's Quick Ratio for the trailling 12 Months

AKCA Quick Ratio

 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth -0.63 % 3.41 % 57.83 % 13.52 % -14.83 %
Y / Y Cash & cash equivalent TTM Growth 28.33 % 12.28 % 11.17 % -7 % 1.47 %
Quick Ratio TTM 10.64 10.01 8.34 7.36 8.24
Total Ranking TTM # 3932 # 100 # 4103 # 0 # 0
Seq. Current Liabilities TTM Growth 0.31 % -10.49 % 4.83 % 5.58 % 4.38 %
Seq. Cash & cash equivalent TTM Growth 6.58 % 7.46 % 18.8 % -5.68 % -6.76 %

Quick ratio ranking by company, industry and sector >> Back to AKCA Financial Strength Comparisons >> Go to Compare AKCA Quick Ratio to its Competitors

On the trailing twelve months basis AKCA Cash & cash equivalent grew by 31.89 % in Q2 2020 year on year, faster than Current Liabilities, this led to increase in in Akcea Therapeutics Inc 's Quick Ratio to 10.64, above AKCA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 448 other companies have achieved higher Quick Ratio than Akcea Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2020 from 100 to 3932.

Explain Quick Ratio?
How much Cash & cash equivalents AKCA´s has?
What are AKCA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 449
Healthcare Sector # 846
Within the Market # 3932


trailing twelve months Quick Ratio Statistics
High Average Low
9.75 8.38 7.06
(Jun 30 2020)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2020, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2020 MRQ Cash & cash equivalentJun 30 2020 MRQ Current Liabilities
Atrium Therapeutics Inc   30.33 $ 352.446  Millions$ 11.620  Millions
Viking Therapeutics Inc   30.10 $ 263.002  Millions$ 8.737  Millions
Ligand Pharmaceuticals Incorporated  27.67 $ 809.880  Millions$ 29.264  Millions
Ideaya Biosciences Inc   27.40 $ 170.414  Millions$ 6.220  Millions
Generation Bio Co   26.10 $ 301.086  Millions$ 11.536  Millions
Pliant Therapeutics Inc   25.96 $ 312.468  Millions$ 12.036  Millions
Biospecifics Technologies Corp  25.78 $ 99.052  Millions$ 3.842  Millions
Cryoport inc   24.96 $ 208.753  Millions$ 8.362  Millions
Calliditas Therapeutics Ab  24.52 $ 156.823  Millions$ 6.395  Millions
Rezolute Inc   24.00 $ 77.434  Millions$ 3.226  Millions
Silo Pharma Inc  23.96 $ 1.919  Millions$ 0.080  Millions
Applied Molecular Transport Inc   23.76 $ 163.263  Millions$ 6.870  Millions
Assembly Biosciences Inc   23.47 $ 226.714  Millions$ 9.659  Millions
Allakos Inc   23.24 $ 454.946  Millions$ 19.579  Millions
Lexaria Bioscience Corp   22.55 $ 2.052  Millions$ 0.091  Millions
Monopar Therapeutics Inc   21.89 $ 12.546  Millions$ 0.573  Millions
Gossamer Bio Inc   21.80 $ 600.364  Millions$ 27.544  Millions
Scpharmaceuticals Inc   21.72 $ 119.329  Millions$ 5.494  Millions
Constellation Pharmaceuticals Inc  21.38 $ 520.513  Millions$ 24.347  Millions
Palatin Technologies Inc   21.09 $ 82.852  Millions$ 3.928  Millions
Myokardia Inc   20.87 $ 918.053  Millions$ 43.991  Millions
Iveric Bio Inc   20.79 $ 245.735  Millions$ 11.818  Millions
Crinetics Pharmaceuticals Inc   20.79 $ 205.165  Millions$ 9.870  Millions
Neurogene Inc   20.51 $ 129.596  Millions$ 6.320  Millions
Filana Therapeutics Inc   19.90 $ 25.254  Millions$ 1.269  Millions
Hoth Therapeutics Inc   19.60 $ 6.959  Millions$ 0.355  Millions
Atreca inc   19.52 $ 143.518  Millions$ 7.353  Millions
Trevena inc   19.15 $ 54.795  Millions$ 2.862  Millions
Capricor Therapeutics inc   18.91 $ 36.253  Millions$ 1.918  Millions
Enanta Pharmaceuticals Inc  18.83 $ 370.000  Millions$ 19.650  Millions

Date modified: 2026-08-29T17:40:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.